KR101881791B1 - 비진정성 덱스메데토미딘 경피 조성물을 사용하여 금단 증후군을 치료하기 위한 방법 및 조성물 - Google Patents

비진정성 덱스메데토미딘 경피 조성물을 사용하여 금단 증후군을 치료하기 위한 방법 및 조성물 Download PDF

Info

Publication number
KR101881791B1
KR101881791B1 KR1020187004780A KR20187004780A KR101881791B1 KR 101881791 B1 KR101881791 B1 KR 101881791B1 KR 1020187004780 A KR1020187004780 A KR 1020187004780A KR 20187004780 A KR20187004780 A KR 20187004780A KR 101881791 B1 KR101881791 B1 KR 101881791B1
Authority
KR
South Korea
Prior art keywords
compositions
methods
dexmedetomidine transdermal
withdrawal syndromes
treating withdrawal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020187004780A
Other languages
English (en)
Korean (ko)
Other versions
KR20180021902A (ko
Inventor
아드차라 퐁피라파트
아밋 제인
브렛 버너
지안예 웬
주타로 슈도
Original Assignee
테이코쿠 팔마 유에스에이, 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 테이코쿠 팔마 유에스에이, 인코포레이티드 filed Critical 테이코쿠 팔마 유에스에이, 인코포레이티드
Publication of KR20180021902A publication Critical patent/KR20180021902A/ko
Application granted granted Critical
Publication of KR101881791B1 publication Critical patent/KR101881791B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/417—Imidazole-alkylamines, e.g. histamine, phentolamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Addiction (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
KR1020187004780A 2013-10-07 2014-10-03 비진정성 덱스메데토미딘 경피 조성물을 사용하여 금단 증후군을 치료하기 위한 방법 및 조성물 Active KR101881791B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361887871P 2013-10-07 2013-10-07
US61/887,871 2013-10-07
PCT/US2014/059058 WO2015054063A1 (en) 2013-10-07 2014-10-03 Methods and compositions for treating withdrawal syndromes using non-sedative dexmedetomidine transdermal compositions

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020167010340A Division KR20160055934A (ko) 2013-10-07 2014-10-03 비진정성 덱스메데토미딘 경피 조성물을 사용하여 금단 증후군을 치료하기 위한 방법 및 조성물

Publications (2)

Publication Number Publication Date
KR20180021902A KR20180021902A (ko) 2018-03-05
KR101881791B1 true KR101881791B1 (ko) 2018-07-25

Family

ID=52777130

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020187004780A Active KR101881791B1 (ko) 2013-10-07 2014-10-03 비진정성 덱스메데토미딘 경피 조성물을 사용하여 금단 증후군을 치료하기 위한 방법 및 조성물
KR1020167010340A Ceased KR20160055934A (ko) 2013-10-07 2014-10-03 비진정성 덱스메데토미딘 경피 조성물을 사용하여 금단 증후군을 치료하기 위한 방법 및 조성물

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020167010340A Ceased KR20160055934A (ko) 2013-10-07 2014-10-03 비진정성 덱스메데토미딘 경피 조성물을 사용하여 금단 증후군을 치료하기 위한 방법 및 조성물

Country Status (11)

Country Link
US (1) US20150098983A1 (https=)
EP (1) EP3054934B1 (https=)
JP (1) JP6231670B2 (https=)
KR (2) KR101881791B1 (https=)
CN (1) CN105682650B (https=)
CA (1) CA2924190C (https=)
ES (1) ES2983565T3 (https=)
FI (1) FI3054934T3 (https=)
RU (1) RU2648817C2 (https=)
TW (1) TWI624278B (https=)
WO (1) WO2015054063A1 (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2924233C (en) * 2013-10-07 2018-10-23 Teikoku Pharma Usa, Inc. Methods and compositions for treating attention deficit hyperactivity disorder, anxiety and insomnia using dexmedetomidine transdermal compositions
GB201600918D0 (en) * 2016-01-18 2016-03-02 Buzzz Pharmaceuticals Ltd Transdermal patch
BR112019006955A2 (pt) 2016-10-31 2019-07-02 Teikoku Pharma Usa Inc métodos de controle da dor usando dispositivos de distribuição transdérmica de dexmedetomidina
IL267689B2 (en) 2016-12-31 2025-05-01 Bioxcel Therapeutics Inc Use of sublingual dexmedetomidine for the treatment of agitation
CN111447927A (zh) * 2017-12-08 2020-07-24 帝国制药美国公司 纳洛酮经皮给药装置及其使用方法
EP3813828A4 (en) * 2018-06-27 2022-03-30 Bioxcel Therapeutics, Inc. METHOD OF TREATMENT OF AGITATION WITH DEXMEDETOMIDIN HYDROCHLORIDE
BR112020026672A2 (pt) 2018-06-27 2021-03-30 Bioxcel Therapeutics, Inc. Formulações de filme contendo dexmedetomidina e métodos para produzi-las
CN112996491A (zh) * 2018-10-15 2021-06-18 阿姆农·瓦尔迪 缓释大麻素及其产品
WO2020084065A1 (en) * 2018-10-24 2020-04-30 Saniona A/S Transdermal tropane compositions and methods for using the same
CA3135552C (en) * 2019-04-17 2023-09-26 Lts Lohmann Therapie-Systeme Ag Ketamine containing transdermal therapeutic system comprising free hydroxyl groups
BR112022000992A2 (pt) * 2019-07-19 2022-06-14 Arx Llc Regimes de tratamento de dexmedetomidina não sedantes
JP7495989B2 (ja) 2020-02-14 2024-06-05 テイコク ファーマ ユーエスエー インコーポレーテッド 局所用ナロキソン組成物およびそれを使用するための方法
US20240024289A1 (en) * 2020-10-08 2024-01-25 Bioxcel Therapeutics, Inc. Treatment of bipolar disorders and psychosis using dexmedetomidine hydrochloride
JP2024502082A (ja) * 2021-01-04 2024-01-17 バイオエクセル セラピューティクス，インコーポレイテッド デクスメデトミジン治療レジメン
CN115227638B (zh) * 2022-07-19 2025-03-18 广州新济生物医药研究院有限公司 一种盐酸右美托咪定可溶性微针及其制备方法
US11806334B1 (en) 2023-01-12 2023-11-07 Bioxcel Therapeutics, Inc. Non-sedating dexmedetomidine treatment regimens
AU2024253436A1 (en) * 2023-04-04 2025-11-13 Board Of Regents, The University Of Texas System Combinations including methocinnamox

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130072532A1 (en) 2010-01-08 2013-03-21 Recro Pharma, Inc. Topical transdermal dexmedetomidine compositions and methods of use thereof

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5217718A (en) * 1989-08-18 1993-06-08 Cygnus Therapeutic Systems Method and device for administering dexmedetomidine transdermally
US5124157A (en) * 1989-08-18 1992-06-23 Cygnus Therapeutic Systems Method and device for administering dexmedetomidine transdermally
GB9111732D0 (en) * 1991-05-31 1991-07-24 Orion Yhtymae Oy The use of certain salts of medetomidine and its optically active enantiomers to regulate the rate of transdermal administration of the drugs
CN1188189C (zh) * 1995-06-07 2005-02-09 奥瑟－麦内尔制药公司 基质层含有17－脱乙酰基诺孕酯的经皮贴片及基质的用途
GB9521680D0 (en) * 1995-10-23 1996-01-03 Orion Yhtymo Oy New use of imidazole derivatives
US5891868A (en) * 1997-11-21 1999-04-06 Kaiser Foundation Health Plan, Inc. Methods for treating postmenopausal women using ultra-low doses of estrogen
MXPA01003310A (es) * 1998-10-02 2003-05-15 3M Innovative Properties Co Sistema de suministro de farmaco originados en mucosa y aplicaciones animales.
US20030170195A1 (en) * 2000-01-10 2003-09-11 Noven Pharmaceuticals, Inc. Compositions and methods for drug delivery
TWI341735B (en) * 2003-07-31 2011-05-11 Hisamitsu Pharmaceutical Co Adhesive preparations
EP2062575B1 (en) * 2006-09-11 2012-02-15 Sekisui Chemical Co., Ltd. Adhesive preparation comprising desglymidodrine
EP2286814B1 (en) * 2008-05-15 2013-10-16 Hisamitsu Pharmaceutical Co., Inc. Transdermal preparation containing palonosetron
AU2011331511C1 (en) * 2010-11-17 2018-01-18 Hexal Ag Transdermal therapeutic system comprising buprenorphine
WO2013072763A2 (en) * 2011-11-16 2013-05-23 Nometics Inc. Non-sensitizing transdermal clonidine patch
WO2013090278A2 (en) * 2011-12-11 2013-06-20 Recro Pharma, Inc. Intranasal dexmedetomidine compositions and methods of use thereof
US8242158B1 (en) * 2012-01-04 2012-08-14 Hospira, Inc. Dexmedetomidine premix formulation
HUE035312T2 (en) * 2012-01-31 2018-05-02 Gruenenthal Gmbh Pharmaceutical patch (1R, 4R) -6'-fluoro-N, N-dimethyl-4-phenyl-4 ', 9'-dihydro-3'H-spiro [cyclohexane-1,1'-pyrano [3,4- b] for transdermal administration of indole] -4-amine

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130072532A1 (en) 2010-01-08 2013-03-21 Recro Pharma, Inc. Topical transdermal dexmedetomidine compositions and methods of use thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
American Journal of Health-System Pharmacy, Vol. 68, Pages 1233-1238 (2011)*
Prim Care Companion J Clin Psychiatry. 12(3): PCC.10r00991.(2010)*

Also Published As

Publication number Publication date
TWI624278B (zh) 2018-05-21
RU2648817C2 (ru) 2018-03-28
ES2983565T3 (es) 2024-10-23
WO2015054063A1 (en) 2015-04-16
CA2924190A1 (en) 2015-04-16
EP3054934A4 (en) 2017-04-05
KR20180021902A (ko) 2018-03-05
EP3054934A1 (en) 2016-08-17
US20150098983A1 (en) 2015-04-09
JP2016532643A (ja) 2016-10-20
CN105682650A (zh) 2016-06-15
JP6231670B2 (ja) 2017-11-15
KR20160055934A (ko) 2016-05-18
EP3054934B1 (en) 2024-05-22
FI3054934T3 (fi) 2024-07-19
TW201521799A (zh) 2015-06-16
RU2016109632A (ru) 2017-11-15
CA2924190C (en) 2019-07-09
BR112016006200A2 (pt) 2017-08-01
CN105682650B (zh) 2020-09-25

Similar Documents

Publication Publication Date Title
KR101881791B1 (ko) 비진정성 덱스메데토미딘 경피 조성물을 사용하여 금단 증후군을 치료하기 위한 방법 및 조성물
EP3080143A4 (en) Methods and compositions for treating hemophilia
EP3054932A4 (en) Dexmedetomidine transdermal delivery devices and methods for using the same
EP3060207A4 (en) Methods and compositions for treating cancer
EP3054940A4 (en) Compositions and methods for treating non-alcoholic steatohepatitis
SMT201900635T1 (it) Composizioni e metodi di attivazione della segnalazione dipendente dallo "stimolatore di geni interferone"
EP2830654B8 (en) Methods and compositions for treating inflammation
EP3007695A4 (en) Compositions and methods for treating anemia
EP3077049A4 (en) Compositions and methods for treating vitiligo
EP3054931A4 (en) Methods and compositions for managing pain comprising dexmedetomidine transdermal compositions
EP3033427A4 (en) Compositions and methods for controlling pain
EP3077823A4 (en) Compositions and methods for identifying and treating cachexia or pre-cachexia
EP3052510A4 (en) Methods and compositions for treating and/or preventing mucositis
IL239921A0 (en) Preparations containing solutions in solid state and their use for the treatment of pain
EP3033081A4 (en) Compositions and methods for treating chronic urticaria
EP3054930A4 (en) Methods and compositions for transdermal delivery of a non-sedative amount of dexmedetomidine
EP3066472A4 (en) Compositions and methods for detecting and/or treating inflammation
EP3065829A4 (en) Compositions and methods for treating melanoma
EP3065550A4 (en) Methods and compositions for treating sepsis
EP3052102A4 (en) Compositions and methods for treating cancers
EP3004395A4 (en) Compositions and methods for treating cancer
EP3074022A4 (en) Compositions and methods for inhibiting intercellular interactions
SG11201505907PA (en) Compositions and methods for pain relief without numbness
EP3082859A4 (en) Compositions and methods for treating sarcoma
EP2984185A4 (en) Methods and compositions for treating cancer

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20180219

Application number text: 1020167010340

Filing date: 20160420

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20180405

Comment text: Request for Examination of Application

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20180529

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20180719

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20180720

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
PR1001 Payment of annual fee

Payment date: 20220615

Start annual number: 5

End annual number: 5

PR1001 Payment of annual fee

Payment date: 20230615

Start annual number: 6

End annual number: 6

PR1001 Payment of annual fee

Payment date: 20240619

Start annual number: 7

End annual number: 7

PR1001 Payment of annual fee

Payment date: 20250616

Start annual number: 8

End annual number: 8